Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a leading player in the regenerative medicine sector, is headquartered in the United States. Founded in 1985, the company has established itself as a pioneer in advanced wound care and surgical biologics, focusing on innovative solutions that enhance healing and improve patient outcomes. With a strong presence across North America, Organogenesis offers a diverse portfolio of products, including allograft and xenograft tissue products, which are distinguished by their unique biological properties and effectiveness. The company has achieved significant milestones, including FDA approvals for several of its key offerings, solidifying its position in the market. Recognised for its commitment to quality and innovation, Organogenesis continues to lead the way in transforming patient care through its cutting-edge therapies and comprehensive support services.
DitchCarbon Score
How does Organogenesis Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organogenesis Holdings Inc.'s score of 31 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organogenesis Holdings Inc.'s reported carbon emissions
Organogenesis Holdings Inc., headquartered in the US, has set ambitious climate commitments aimed at significantly reducing its carbon emissions. The company has established a target to achieve a 42% absolute reduction in Scope 1 and 2 greenhouse gas (GHG) emissions by 2030, using 2021 as the baseline year. This commitment reflects a proactive approach to mitigating climate impact. In addition to its near-term goals, Organogenesis aims for Net Zero emissions across all scopes (Scope 1, 2, and 3) by 2045, again referencing a 2021 baseline. These targets underscore the company's dedication to sustainability and its role in addressing climate change. Currently, there is no specific emissions data available for Organogenesis Holdings Inc. However, the outlined reduction initiatives demonstrate a clear strategy for enhancing environmental performance and contributing to global climate goals.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Organogenesis Holdings Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
